

Jonathan Kimmelman

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7954041/jonathan-kimmelman-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155
papers

4,476
citations

30
h-index

64
g-index

166
ext. papers

5,262
ext. citations

9.5
avg, IF

6.26
L-index

#	Paper	IF	Citations
155	Sunburn and p53 in the onset of skin cancer. <i>Nature</i> , 1994 , 372, 773-6	50.4	1520
154	Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. <i>PLoS Medicine</i> , 2013 , 10, e1001489	11.6	182
153	Against pandemic research exceptionalism. <i>Science</i> , 2020 , 368, 476-477	33.3	171
152	Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. <i>Clinical Trials</i> , 2015 , 12, 77-83	2.2	158
151	Distinguishing between exploratory and confirmatory preclinical research will improve translation. <i>PLoS Biology</i> , 2014 , 12, e1001863	9.7	136
150	Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. <i>Stem Cell Reports</i> , 2016 , 6, 787-797	8	136
149	Analysis of consent validity for invasive, nondiagnostic research procedures. <i>IRB: Ethics & Human Research</i> , 2012 , 34, 1-7		95
148	SCIENTIFIC COMMUNITY. Confronting stem cell hype. <i>Science</i> , 2016 , 352, 776-7	33.3	86
147	Are outcome-adaptive allocation trials ethical?. <i>Clinical Trials</i> , 2015 , 12, 102-6	2.2	77
146	The therapeutic misconception at 25: treatment, research, and confusion. <i>Hastings Center Report</i> , 2007 , 37, 36-42	3.3	77
145	Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. <i>PLoS Medicine</i> , 2011 , 8, e1001010	11.6	65
144	The questionable use of unequal allocation in confirmatory trials. <i>Neurology</i> , 2014 , 82, 77-9	6.5	61
143	Recent developments in gene transfer: risk and ethics. <i>BMJ, The</i> , 2005 , 330, 79-82	5.9	60
142	Should preclinical studies be registered?. <i>Nature Biotechnology</i> , 2012 , 30, 488-9	44.5	57
141	Where Have All the Rodents Gone? The Effects of Attrition in Experimental Research on Cancer and Stroke. <i>PLoS Biology</i> , 2016 , 14, e1002331	9.7	55
140	Research ethics. Beyond access vs. protection in trials of innovative therapies. <i>Science</i> , 2010 , 328, 829-30	33.3	54
139	Risk of surgical delivery to deep nuclei: a meta-analysis. <i>Movement Disorders</i> , 2011 , 26, 1415-21	7	43

138	Helsinki discords: FDA, ethics, and international drug trials. <i>Lancet, The</i> , 2009 , 373, 13-4	40	43
137	Preclinical efficacy studies in investigator brochures: Do they enable risk-benefit assessment?. <i>PLoS Biology</i> , 2018 , 16, e2004879	9.7	39
136	Consider drug efficacy before first-in-human trials. <i>Nature</i> , 2017 , 542, 25-27	50.4	38
135	Faithful companions: a proposal for neurooncology trials in pet dogs. <i>Cancer Research</i> , 2007 , 67, 4541-4	10.1	37
134	Harms From Uninformative Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 813-814	27.4	36
133	Gene Transfer and the Ethics of First-in-Human Research: Lost in Translation 2009 ,		36
132	Is Participation in Cancer Phase I Trials Really Therapeutic?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 135-138	32	35
131	The structure of clinical translation: efficiency, information, and ethics. <i>Hastings Center Report</i> , 2015 , 45, 27-39	3.3	34
130	Policy: Global standards for stem-cell research. <i>Nature</i> , 2016 , 533, 311-3	50.4	33
129	New ISSCR guidelines: clinical translation of stem cell research. <i>Lancet, The</i> , 2016 , 387, 1979-81	40	33
128	Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	32
127	A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries. <i>Trials</i> , 2012 , 13, 173	2.8	32
126	Extending clinical equipoise to phase 1 trials involving patients: unresolved problems. <i>Kennedy Institute of Ethics Journal</i> , 2010 , 20, 75-98	1.1	29
125	Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations. <i>Movement Disorders</i> , 2009 , 24, 1893-901	7	28
124	A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib. <i>ELife</i> , 2015 , 4, e08351	8.9	27
123	ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. <i>Stem Cell Reports</i> , 2021 , 16, 1398-1408	8	27
122	Research ethics. Rethinking research ethics: the case of postmarketing trials. <i>Science</i> , 2012 , 336, 544-5	33.3	26
121	Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. <i>PLoS Biology</i> , 2017 , 15, e2000487	9.7	26

120	Increasing efficiency of preclinical research by group sequential designs. <i>PLoS Biology</i> , 2017 , 15, e20013077	2.7	25
119	Assessing risk/benefit for trials using preclinical evidence: a proposal. <i>Journal of Medical Ethics</i> , 2016 , 42, 50-3	2.5	25
118	Valuing risk: the ethical review of clinical trial safety. <i>Kennedy Institute of Ethics Journal</i> , 2004 , 14, 369-93	1.1	24
117	Ethical considerations of e-cigarette use for tobacco harm reduction. <i>Respiratory Research</i> , 2016 , 17, 53	7.3	24
116	The paradox of precision medicine. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 341-342	19.4	23
115	Potential harms from legalization of recreational cannabis use in Canada. <i>Canadian Journal of Public Health</i> , 2019 , 110, 222-226	3.2	21
114	Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials. <i>BMJ, The</i> , 2015 , 350, h1116	5.9	21
113	Publication and reporting conduct for pharmacodynamic analyses of tumor tissue in early-phase oncology trials. <i>Clinical Cancer Research</i> , 2012 , 18, 6478-84	12.9	21
112	Medical Research, Risk, and Bystanders. <i>IRB: Ethics & Human Research</i> , 2005 , 27, 1		21
111	Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. <i>PLoS Medicine</i> , 2018 , 15, e1002505	11.6	20
110	Patient-Funded Trials: Opportunity or Liability?. <i>Cell Stem Cell</i> , 2015 , 17, 135-7	18	19
109	Ethical development of stem-cell-based interventions. <i>Nature Medicine</i> , 2019 , 25, 1037-1044	50.5	17
108	The risk-escalation model: a principled design strategy for early-phase trials. <i>Kennedy Institute of Ethics Journal</i> , 2014 , 24, 121-39	1.1	17
107	Evaluation of Journal Registration Policies and Prospective Registration of Randomized Clinical Trials of Nonregulated Health Care Interventions. <i>JAMA Internal Medicine</i> , 2019 , 179, 624-632	11.5	16
106	Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. <i>Neurology</i> , 2020 , 94, e1-e14	6.5	16
105	Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications: A Systematic Review. <i>JAMA Internal Medicine</i> , 2019 , 179, 90-97	11.5	16
104	Elements of informed consent and decision quality were poorly correlated in informed consent documents. <i>Journal of Clinical Epidemiology</i> , 2015 , 68, 1472-80	5.7	15
103	Elements of style: consent form language and the therapeutic misconception in phase 1 gene transfer trials. <i>Human Gene Therapy</i> , 2005 , 16, 502-8	4.8	15

102	Why clinical translation cannot succeed without failure. <i>ELife</i> , 2015 , 4, e12844	8.9	15
101	The bench is closer to the bedside than we think: Uncovering the ethical ties between preclinical researchers in translational neuroscience and patients in clinical trials. <i>PLoS Biology</i> , 2018 , 16, e2006343	9.7	15
100	Burdensome Research Procedures in Trials: Why Less Is More. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	14
99	Stable ethics: enrolling non-treatment-refractory volunteers in novel gene transfer trials. <i>Molecular Therapy</i> , 2007 , 15, 1904-6	11.7	14
98	Can cancer researchers accurately judge whether preclinical reports will reproduce?. <i>PLoS Biology</i> , 2017 , 15, e2002212	9.7	14
97	Ethics, ambiguity aversion, and the review of complex translational clinical trials. <i>Bioethics</i> , 2012 , 26, 242-50	2	13
96	Missing the forest: further thoughts on the ethics of bystander risk in medical research. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2007 , 16, 483-90	0.9	13
95	Imatinib and the long tail of targeted drug development. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 1-3	19.4	13
94	Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy. <i>Cancer Research</i> , 2016 , 76, 4627-36	10.1	12
93	Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy. <i>Hastings Center Report</i> , 2019 , 49, 31-41	3.3	12
92	Trials that say "maybe": the disconnect between exploratory and confirmatory testing after drug approval. <i>BMJ, The</i> , 2018 , 360, k959	5.9	11
91	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. <i>Molecular Therapy - Oncolytics</i> , 2019 , 14, 179-187	6.4	11
90	Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross-sectional study. <i>British Journal of Pharmacology</i> , 2018 , 175, 4229-4238	8.6	11
89	A systematic review and meta-analysis of pregabalin preclinical studies. <i>Pain</i> , 2020 , 161, 684-693	8	10
88	Are phase 1 trials therapeutic? Risk, ethics, and division of labor. <i>Bioethics</i> , 2014 , 28, 138-46	2	9
87	Ethical and Policy Issues for Seamless Phase I Oncology Trials. <i>Journal of Clinical Oncology</i> , 2020 , 38, 669-673	6.7	9
86	Do We Know Whether Researchers and Reviewers are Estimating Risk and Benefit Accurately?. <i>Bioethics</i> , 2016 , 30, 609-17	2	9
85	Medical research, risk, and bystanders. <i>IRB: Ethics & Human Research</i> , 2005 , 27, 1-6		9

84	Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 719-720	19.4	8
83	The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 832-846	7	8
82	Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 886-892	9.7	8
81	Expert Forecasts of COVID-19 Vaccine Development Timelines. <i>Journal of General Internal Medicine</i> , 2020 , 35, 3753-3755	4	8
80	The stem cell market and policy options: a call for clarity. <i>Journal of Law and the Biosciences</i> , 2018 , 5, 743-758	4.1	8
79	Consent for nondiagnostic research biopsies: a pilot study of participant recall and therapeutic orientation. <i>IRB: Ethics & Human Research</i> , 2014 , 36, 9-15		8
78	Rejoinder. <i>Clinical Trials</i> , 2015 , 12, 125-7	2.2	7
77	Beyond human subjects: risk, ethics, and clinical development of nanomedicines. <i>Journal of Law, Medicine and Ethics</i> , 2012 , 40, 841-7	1.2	7
76	The social function of clinical equipoise. <i>Clinical Trials</i> , 2012 , 9, 630-1	2.2	7
75	CLINICAL TRIALS AND SCID ROW: THE ETHICS OF PHASE 1 TRIALS IN THE DEVELOPING WORLD. <i>Developing World Bioethics</i> , 2007 , 7, 128-135	2.6	7
74	Ethics of cancer gene transfer clinical research. <i>Methods in Molecular Biology</i> , 2009 , 542, 423-45	1.4	7
73	Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases. <i>Annals of Internal Medicine</i> , 2021 , 174, 326-334	8	7
72	Let's do better: public representations of COVID-19 science. <i>Facets</i> , 2021 , 6, 403-423	2.3	7
71	Nonpublication of trial results for new neurological drugs: A systematic review. <i>Annals of Neurology</i> , 2017 , 81, 782-789	9.4	6
70	Accelerated Drug Approval and Health Inequality. <i>JAMA Internal Medicine</i> , 2016 , 176, 883-4	11.5	6
69	Position statement on the provision and procurement of human eggs for stem cell research. <i>Cell Stem Cell</i> , 2013 , 12, 285-91	18	6
68	Ethics, error, and initial trials of efficacy. <i>Science Translational Medicine</i> , 2013 , 5, 184fs16	17.5	6
67	Tomorrow, interrupted? Risk, ethics, and medical advance in gene transfer. <i>Molecular Therapy</i> , 2009 , 17, 1838-9	11.7	6

66	Inventors as investigators: the ethics of patents in clinical trials. <i>Academic Medicine</i> , 2007 , 82, 24-31	3.9	6
65	Participant Protection in Phase 1 Pediatric Cancer Trials. <i>JAMA Pediatrics</i> , 2019 , 173, 8-9	8.3	6
64	The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing. <i>Oncologist</i> , 2017 , 22, 89-96	5.7	5
63	Clinical Trials in Medical Center Advertising. <i>JAMA Oncology</i> , 2018 , 4, 769-770	13.4	5
62	Better to be in The Placebo Arm for Trials of Neurological Therapies?. <i>Cell Transplantation</i> , 2018 , 27, 677-681	4	5
61	Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1003-1004	27.4	5
60	Comparison between protocols and publications for prognostic and predictive cancer biomarker studies. <i>Clinical Trials</i> , 2020 , 17, 61-68	2.2	5
59	Regulating impact on bystanders in clinical trials: An unsettled frontier. <i>Clinical Trials</i> , 2019 , 16, 450-454	2.2	4
58	Can Oncologists Predict the Efficacy of Treatments in Randomized Trials?. <i>Oncologist</i> , 2021 , 26, 56-62	5.7	4
57	The Effect of Overdose Education and Naloxone Distribution: An Umbrella Review of Systematic Reviews. <i>American Journal of Public Health</i> , 2021 , 111, e1-e12	5.1	4
56	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinsonis Disease</i> , 2020 , 10, 1047-1055	5.3	3
55	What Research Ethics (Often) Gets Wrong about Minimal Risk. <i>American Journal of Bioethics</i> , 2020 , 20, 42-44	1.1	3
54	How do researchers decide early clinical trials?. <i>Medicine, Health Care and Philosophy</i> , 2016 , 19, 191-8	2	3
53	Clinical trials and SCID row: the ethics of phase 1 trials in the developing world. <i>Developing World Bioethics</i> , 2007 , 7, 128-35	2.6	3
52	What Is Human Research For? Reflections on the Omission of Scientific Integrity from the. <i>Perspectives in Biology and Medicine</i> , 2020 , 63, 251-261	1.5	3
51	Benefit, burden, and impact for a cohort of post-approval cancer combination trials. <i>Clinical Trials</i> , 2020 , 17, 18-29	2.2	3
50	How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence?. <i>International Journal of Cancer</i> , 2019 , 145, 3370-3375	7.5	2
49	Clinical development success rates and social value of pediatric Phase 1 trials in oncology. <i>PLoS ONE</i> , 2020 , 15, e0234911	3.7	2

48	Towards a global human embryonic stem cell bank: differential termination. <i>American Journal of Bioethics</i> , 2007 , 7, 52-3; discussion W4-6	1.1	2
47	Principal investigators over-optimistically forecast scientific and operational outcomes for clinical trials.. <i>PLoS ONE</i> , 2022 , 17, e0262862	3.7	2
46	Protection at the cutting edge: the case for central review of human gene transfer research. <i>Cmaj</i> , 2003 , 169, 781-2	3.5	2
45	Individualized therapy trials: navigating patient care, research goals and ethics. <i>Nature Medicine</i> , 2021 , 27, 1679-1686	50.5	2
44	Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol. <i>F1000Research</i> , 2020 , 9, 485	3.6	2
43	Ethics of Cancer Gene Transfer Clinical Research. <i>Methods in Molecular Biology</i> , 2015 , 1317, 263-85	1.4	2
42	Ethics and Uncertainty: Considerations for the Design and Review of Translational Trials Involving Stem Cells. <i>Pancreatic Islet Biology</i> , 2011 , 403-418	0.4	2
41	Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 859-862	9.7	2
40	Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study. <i>BMJ Open</i> , 2020 , 10, e034306	3	2
39	Systematic review and narrative review lead experts to different cancer trial predictions: a randomized trial. <i>Journal of Clinical Epidemiology</i> , 2021 , 132, 116-124	5.7	2
38	The PLOS Biology XV Collection: 15 Years of Exceptional Science Highlighted across 12 Months. <i>PLoS Biology</i> , 2019 , 17, e3000180	9.7	1
37	Wisdom of the expert crowd prediction of response for 3 neurology randomized trials. <i>Neurology</i> , 2020 , 95, e488-e498	6.5	1
36	Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol. <i>F1000Research</i> , 9, 485	3.6	1
35	Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio		1
34	Reply to 'Correcting the ASCO position on phase I clinical trials in cancer'. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 125-126	19.4	1
33	Why IRBs should protect bystanders in human research. <i>Bioethics</i> , 2020 , 34, 933-936	2	1
32	Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration. <i>JAMA Network Open</i> , 2021 , 4, e2110456	10.4	1
31	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 171-177	7	1

30	Commentary on Kahrass et al: The sublime inertia of informed consent language in early phase clinical trials involving patients. <i>Clinical Trials</i> , 2021 , 18, 81-82	2.2	1
29	Completeness of clinical evidence citation in trial protocols: A cross-sectional analysis.. <i>Med</i> , 2022 , 3, 335-343.e6	31.7	1
28	Is preclinical research in cancer biology reproducible enough?. <i>ELife</i> , 2021 , 10,	8.9	1
27	Organ donor intervention trials and the ethical challenge of bystander organ recipients. <i>Clinical Trials</i> , 2019 , 16, 461-462	2.2	0
26	How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov.. <i>PLoS ONE</i> , 2022 , 17, e0262114	3.7	0
25	Ethical Considerations for Phase I Trials in Oncology.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102125	2.2	0
24	Ethical Review and Methodologic Innovation in Phase 1 Cancer Trials-Reply. <i>JAMA Pediatrics</i> , 2019 , 173, 609-610	8.3	
23	Decision analysis approach to risk/benefit evaluation in the ethical review of controlled human infection studies. <i>Bioethics</i> , 2020 , 34, 764-770	2	
22	Introduction: gene transfer lost in translation1-7		
21	The chasm: the ethics of initiating first-in-human clinical trials110-131		
20	Tropic of cancers: gene transfer in resource-poor settings132-152		
19	Something in the sight adjusts itself: conclusions178-191		
18	Battling a thousand points of might. <i>Hastings Center Report</i> , 2009 , 39, 3	3.3	
17	Clinical Trials, Ethics, and Human Protections Policies 2020 , 1-18		
16	Clinical Translation in Central Nervous System Diseases: Ethical and Social Challenges 2015 , 1107-1124		
15	Ensemble Space and the Ethics of Clinical Development. <i>Research Ethics Forum</i> , 2016 , 137-151	0.2	
14	Group sample sizes in nonregulated health care intervention trials described as randomized controlled trials were overly similar. <i>Journal of Clinical Epidemiology</i> , 2020 , 120, 8-16	5.7	
13	Response to Moisset et al. <i>Pain</i> , 2020 , 161, 2427-2428	8	

12	The Research Optimist's Defense. <i>Perspectives in Biology and Medicine</i> , 2016 , 59, 491-506	1.5
11	The proportion of North American cancer trials that evaluate novel targets. <i>Investigational New Drugs</i> , 2021 , 39, 256-259	4.3
10	Ethical issues in the development of oncology drugs. <i>Clinical Advances in Hematology and Oncology</i> , 2018 , 16, 644-647	0.6
9	Relationship between lay and expert perceptions of COVID-19 vaccine development timelines in Canada and USA.. <i>PLoS ONE</i> , 2022 , 17, e0262740	3.7
8	Interventions for physician prescribers of opioids for chronic non-cancer pain: protocol for an overview of systematic reviews.. <i>BMJ Open</i> , 2022 , 12, e060964	3
7	Practical steps to identifying the research risk of pragmatic trials.. <i>Clinical Trials</i> , 2022 , 17407745211063476	4.6
6	Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911	
5	Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911	
4	Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911	
3	Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911	
2	Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911	
1	Clinical development success rates and social value of pediatric Phase 1 trials in oncology 2020 , 15, e0234911	